Physician profile
John M Iverson
NPI 1467864470
$2,630.47
in general payments reported to CMS, 2019-2025
33 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $356 · 2023: $820 · 2024: $828 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $394.58 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $269.34 | 2022-2025 | Prolia, Evenity, Repatha |
| Glaxosmithkline, LLC. | $241.92 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $199.21 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $115.52 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $110.72 | 2021-2023 | |
| Abbott Laboratories | $105.28 | 2022-2024 | Proclaim, Freestyle Libre 3, Mitraclip |
| Lilly USA, LLC | $72.92 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Nestle Healthcare Nutrition INC. | $61.15 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.11 | 2022-2025 | |
| Lucid Diagnostics INC. | $55.15 | 2023-2024 | |
| Indivior INC. | $43.06 | 2024 | Sublocade |
| Stryker Corporation | $42.79 | 2021 | |
| Neurocrine Biosciences, INC. | $39.71 | 2024 | Ingrezza |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $35.92 | 2023 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $34.27 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $34.21 | 2021-2022 | |
| Medtronic, INC. | $32.81 | 2021 | |
| Collegium Pharmaceutical, INC. | $32.62 | 2023 | Xtampza, Belbuca |
| Mylan Specialty L.P. | $26.47 | 2024 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $24.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.68 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.65 | 2025 | Recorlev |
| Dexcom, INC. | $18.85 | 2025 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $17.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.22 | 2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $14.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.56 | 2022 | |
| Itamar Medical INC | $14.18 | 2022 | |
| Currax Pharmaceuticals LLC | $13.49 | 2024 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $12.92 | 2022 | |
| Merck Sharp & Dohme LLC | $12.73 | 2023 | Belsomra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Iverson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.